Optimizing Access to Liquid Biopsy in the Present and Future Cancer Landscape
Overview
Overview
Authors
Authors
Affiliations
Affiliations
Soon will be listed here.
Abstract
We discuss a recent manuscript providing recommendations to improve use and access for liquid biopsy in oncology.
Citing Articles
Deficits of Molecular Prognosis/Diagnosis Studies in Underserved Populations.
Medford A, Moy B JCO Oncol Pract. 2024; 20(11):1515-1522.
PMID: 39531843 PMC: 11747936. DOI: 10.1200/OP.24.00131.
References
1.
Kasi P, Fehringer G, Taniguchi H, Starling N, Nakamura Y, Kotani D
. Impact of Circulating Tumor DNA-Based Detection of Molecular Residual Disease on the Conduct and Design of Clinical Trials for Solid Tumors. JCO Precis Oncol. 2022; 6:e2100181.
PMC: 8926064.
DOI: 10.1200/PO.21.00181.
View
2.
Bidard F, Hardy-Bessard A, Dalenc F, Bachelot T, Pierga J, de La Motte Rouge T
. Switch to fulvestrant and palbociclib versus no switch in advanced breast cancer with rising ESR1 mutation during aromatase inhibitor and palbociclib therapy (PADA-1): a randomised, open-label, multicentre, phase 3 trial. Lancet Oncol. 2022; 23(11):1367-1377.
DOI: 10.1016/S1470-2045(22)00555-1.
View
3.
Chakravarty D, Johnson A, Sklar J, Lindeman N, Moore K, Ganesan S
. Somatic Genomic Testing in Patients With Metastatic or Advanced Cancer: ASCO Provisional Clinical Opinion. J Clin Oncol. 2022; 40(11):1231-1258.
DOI: 10.1200/JCO.21.02767.
View
4.
Medford A, Oshry L, Boyraz B, Kiedrowski L, Menshikova S, Butusova A
. TRK inhibitor in a patient with metastatic triple-negative breast cancer and fusions identified cell-free DNA analysis. Ther Adv Med Oncol. 2023; 15:17588359231152844.
PMC: 9893401.
DOI: 10.1177/17588359231152844.
View
5.
Henry N, Somerfield M, Dayao Z, Elias A, Kalinsky K, McShane L
. Biomarkers for Systemic Therapy in Metastatic Breast Cancer: ASCO Guideline Update. J Clin Oncol. 2022; 40(27):3205-3221.
DOI: 10.1200/JCO.22.01063.
View